Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  doxorubicin hydrochloride
Find trials that include:  Any drugs shown
Results 1-25 of 103 for your search:
Start Over
Combination Chemotherapy with or without Rituximab in Treating Younger Patients with Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and under
Trial IDs: ANHL1131, NCI-2012-01963, 2010-019224-31, CDR0000732604, IGR2009/1593, COG-ANHL1131, NCT01595048
Risk-Directed Therapy in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Age: 18 and under
Trial IDs: TOTXVI, NCI-2011-01254, NCT00549848
Combination Chemotherapy and Surgery in Treating Young Patients with Wilms Tumor
Phase: Phase III
Type: Supportive care, Treatment
Age: Under 30 at initial diagnosis
Trial IDs: AREN0534, NCI-2011-01953, CDR0000649716, COG-AREN0534, NCT00945009
Risk-Based Therapy in Treating Younger Patients with Newly Diagnosed Liver Cancer
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 21 and under
Trial IDs: AHEP0731, NCI-2011-01975, CDR0000654889, COG-AHEP0731, NCT02265692, PAHEP0731_A08PAMDREVW01, NCT00980460
Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 0 to 21
Trial IDs: SJBC3, NCI-2011-01251, NCI-2010-00129, NCT01046825
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Supportive care, Treatment
Age: 1 to < 10
Trial IDs: AALL0932, NCI-2011-02599, CDR0000683227, COG-AALL0932, NCT01190930
Combination Chemotherapy in Treating Patients with Non-Metastatic Extracranial Ewing Sarcoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1031, NCI-2011-02611, CDR0000687639, COG-AEWS1031, NCT01231906
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1131, NCI-2011-03797, CDR0000706370, COG-AALL1131, U10CA098543, NCT01406756
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients with High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GOG-0277, NCI-2012-00249, CDR0000724874, IRCI 001, NCT01533207
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: C25003, NCI-2012-03101, 12/LO/1950, 2011-005450-60, JapicCTI-142491, U1111-1161-4937, NCT01712490
Study Comparing AEZS-108/ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) to Doxorubicin as a Second Line Therapy of Endometrial Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AEZS -108-050, NCI-2013-01036, NCT01767155
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SGN35-014, NCI-2013-00462, 2012-002751-42, NCT01777152
Combination Chemotherapy with or without Bortezomib in Treating Younger Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: AALL1231, NCI-2014-00712, NCT02112916
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Hodgkin Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Supportive care, Treatment
Age: 18 and younger
Trial IDs: AHOD1331, NCI-2014-01223, NCT02166463
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients with Non-high Risk Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 17 months and under
Trial IDs: ANBL1232, NCI-2014-00677, NCT02176967
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
Phase: Phase III
Type: Treatment
Age: 18 to 80
Trial IDs: CC-5013-DLC-002, NCI-2015-00282, 2013-004054-21, NCT02285062
Lenalidomide, Rituximab, Cyclophosphamide, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage II-IV Diffuse Large Cell or Grade 3 Follicular Grade B-Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC078E, NCI-2009-01196, Celgene #RV-NHL-PI-0325, RV-NHL-PI-0325, MAYO-MC078E, NCT00670358
Vorinostat and Combination Chemotherapy with Rituximab in Treating Patients with HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-075, NCI-2011-02508, AMC #75, CDR0000683379, NCT01193842
MLN4924, Combination Chemotherapy, and Rituximab in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0216, NCI-2013-01498, 110216, P10797, NCT01415765
Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients with Stage IIB-IV Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 2011-269, NCI-2013-01311, 007884, 11-051, TCN-PM, NCT01697293
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with Stage II-IV HIV-Associated Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-085, NCI-2013-00046, 085, 2014-003678-18, PAMC-085_A05PAMDREVW01, NCT01771107
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1124-CA, NCI-2014-01504, NCT02142049
Start Over